The American Academy of Neurology (AAN) recently opened two pieces of clinical guidance to public comment. A draft guideline, Efficacy and Tolerability of Disease-Modifying Therapies for Children with Spinal Muscular Atrophy, and a guideline protocol, Genetic Testing in Individuals with Cerebral Palsy, are now open to review by individuals interested in providing feedback. Physicians, healthcare professionals, people living with spinal muscular atrophy/cerebral palsy, advocates, and researchers are all invited to provide feedback.
Click here to view Efficacy and Tolerability of Disease-Modifying Therapies for Children with Spinal Muscular Atrophy.
Click here to submit feedback for the draft guideline.
Click here to view Genetic Testing in Individuals with Cerebral Palsy.
Click here to submit feedback on the guideline protocol.
Both public comment windows are open through June 30, 2026.